NASDAQ:ALNY

Alnylam Pharmaceuticals Stock Forecast, Price & News

$175.98

+0.29 (+0.17 %)

(As of 01/26/2021 09:56 AM ET)

Add

Compare

Today's Range

$173.84

Now: $175.98▼

$177.68

50-Day Range

$124.04

MA: $144.28▼

$172.38

52-Week Range

$84.97

Now: $175.98▼

$176.78

Volume1,152 shs

Average Volume993,290 shs

Market Capitalization$20.45 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.47

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP). In addition, the company is developing givosiran for the treatment of patients with AHP; lumasiran for the treatment of primary hyperoxaluria type 1, or PH1; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc., as well as collaboration with Vir Biotechnology, Inc. to advance RNAi therapeutics for the treatment of coronavirus infection, including COVID-19. It also has a collaboration and license agreement with Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational ribonucleic acid interference therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease, as well as Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

MarketRank^™

Overall MarketRank^™

1.57 out of 5 stars

Medical Sector

343rd out of 1,922 stocks

Pharmaceutical Preparations Industry

180th out of 771 stocks

2.3 Analyst's Opinion

Consensus Rating
Alnylam Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 10 buy ratings, 7 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $159.17, Alnylam Pharmaceuticals has a forecasted downside of 9.4% from its current price of $175.69.
Amount of Analyst Coverage
Alnylam Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.3 Community Rank

Outperform Votes
Alnylam Pharmaceuticals has received 1,002 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Alnylam Pharmaceuticals has received 522 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Alnylam Pharmaceuticals has received 65.75% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Alnylam Pharmaceuticals and other stocks. Vote “Outperform” if you believe ALNY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALNY will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Alnylam Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Alnylam Pharmaceuticals does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Alnylam Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,743,373.00 in company stock.
Percentage Held by Insiders
Only 3.50% of the stock of Alnylam Pharmaceuticals is held by insiders.
Percentage Held by Institutions
92.35% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Alnylam Pharmaceuticals are expected to grow in the coming year, from ($7.32) to ($6.21) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Alnylam Pharmaceuticals is -22.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Alnylam Pharmaceuticals is -22.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Alnylam Pharmaceuticals has a P/B Ratio of 13.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:ALNY

Previous Symbol

CUSIP02043Q10

CIK1178670

Webwww.alnylam.com

Phone617-551-8200

Employees1,323

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio5.32

Quick Ratio5.18

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$219.75 million

Price / Sales93.04

Cash FlowN/A

Price / Cash FlowN/A

Book Value$12.90 per share

Price / Book13.64

Profitability

EPS (Most Recent Fiscal Year)($8.11)

Net Income$-886,120,000.00

Net Margins-222.19%

Return on Equity-65.96%

Return on Assets-31.38%

Miscellaneous

Outstanding Shares116,181,000

Market Cap$20.45 billion

Next Earnings Date2/4/2021 (Estimated)

OptionableOptionable

$175.98

+0.29 (+0.17 %)

(As of 01/26/2021 09:56 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive ALNY News and Ratings via Email

Sign-up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter.

Alnylam Pharmaceuticals (NASDAQ:ALNY) Frequently Asked Questions

How has Alnylam Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Alnylam Pharmaceuticals' stock was trading at $101.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ALNY shares have increased by 72.4% and is now trading at $175.69.
View which stocks have been most impacted by COVID-19.

Is Alnylam Pharmaceuticals a buy right now?

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Alnylam Pharmaceuticals stock.
View analyst ratings for Alnylam Pharmaceuticals or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Alnylam Pharmaceuticals?

Wall Street analysts have given Alnylam Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Alnylam Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO?

65 employees have rated Alnylam Pharmaceuticals CEO John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among Alnylam Pharmaceuticals' employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When is Alnylam Pharmaceuticals' next earnings date?

Alnylam Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Alnylam Pharmaceuticals.

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) announced its quarterly earnings data on Tuesday, November, 10th. The biopharmaceutical company reported ($2.18) EPS for the quarter, missing the consensus estimate of ($1.66) by $0.52. The biopharmaceutical company earned $125.85 million during the quarter, compared to the consensus estimate of $119.05 million. Alnylam Pharmaceuticals had a negative trailing twelve-month return on equity of 65.96% and a negative net margin of 222.19%. The company's quarterly revenue was up 79.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.50) EPS.
View Alnylam Pharmaceuticals' earnings history.

What price target have analysts set for ALNY?

18 analysts have issued 1 year target prices for Alnylam Pharmaceuticals' shares. Their forecasts range from $74.00 to $225.00. On average, they expect Alnylam Pharmaceuticals' stock price to reach $159.17 in the next twelve months. This suggests that the stock has a possible downside of 9.4%.
View analysts' price targets for Alnylam Pharmaceuticals or view Wall Street analyst' top-rated stocks.

Who are some of Alnylam Pharmaceuticals' key competitors?

Some companies that are related to Alnylam Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Novavax (NVAX) and United Therapeutics (UTHR).
View all of ALNY's competitors.

What other stocks do shareholders of Alnylam Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).

Who are Alnylam Pharmaceuticals' key executives?

Alnylam Pharmaceuticals' management team includes the following people:

Dr. John M. Maraganore, CEO & Exec. Director (Age 57, Pay $1.79M)
Dr. Yvonne L. Greenstreet M.B.A., MBChB, MBA, Pres & COO (Age 57, Pay $1.14M)
Mr. Jeffrey V. Poulton, Chief Financial Officer (Age 52, Pay $681.75k)
Dr. Akshay K. Vaishnaw, Pres of R&D (Age 57, Pay $986.1k)
Dr. Alfred W. Boyle Ph.D., Sr. VP of Technical Operations
Dr. Kevin Fitzgerald, Sr. VP & Chief Scientific Officer
Ms. Christine Regan Lindenboom, Sr. VP of Investor Relations & Corp. Communications
Ms. Laurie Bartlett Keating J.D., Exec. VP, Chief Legal Officer & Sec. (Age 66)
Ms. Nereyda Garcia, Global Head of Ethics & Compliance
Mr. Mark Baglin, VP of Global Marketing

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Who are Alnylam Pharmaceuticals' major shareholders?

Alnylam Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.14%), Rhenman & Partners Asset Management AB (0.10%), State of Alaska Department of Revenue (0.03%), DNB Asset Management AS (0.01%), Nisa Investment Advisors LLC (0.01%) and IFM Investors Pty Ltd (0.01%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Marsha Fanucci, Philip A Sharp, Phillip A Sharp, Steven M Paul and Yvonne Greenstreet.
View institutional ownership trends for Alnylam Pharmaceuticals.

Which major investors are selling Alnylam Pharmaceuticals stock?

ALNY stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio, Candriam Luxembourg S.C.A., State of Alaska Department of Revenue, and IBM Retirement Fund. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Phillip A Sharp, Steven M Paul, and Yvonne Greenstreet.
View insider buying and selling activity for Alnylam Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Alnylam Pharmaceuticals stock?

ALNY stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Exchange Traded Concepts LLC, Nisa Investment Advisors LLC, DNB Asset Management AS, IFM Investors Pty Ltd, Pacer Advisors Inc., and Gateway Investment Advisers LLC.
View insider buying and selling activity for Alnylam Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Alnylam Pharmaceuticals' stock price today?

One share of ALNY stock can currently be purchased for approximately $175.69.

How big of a company is Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals has a market capitalization of $20.41 billion and generates $219.75 million in revenue each year. The biopharmaceutical company earns $-886,120,000.00 in net income (profit) each year or ($8.11) on an earnings per share basis. Alnylam Pharmaceuticals employs 1,323 workers across the globe.

What is Alnylam Pharmaceuticals' official website?

The official website for Alnylam Pharmaceuticals is www.alnylam.com.

How can I contact Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-551-8200 or via email at [email protected]

This page was last updated on 1/26/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here